By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 128.00 |
Change Today | $ 1.36 |
% Change | 1.07 % |
52 Week High | $214.63 |
52 Week Low | $118.84 |
Volume | 371 |
Shares Issued | 145.80m |
Market Cap | $18,662m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 8 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
15:59 | 150 @ $128.04 |
15:59 | 103 @ $128.04 |
15:59 | 495 @ $128.03 |
15:59 | 1,100 @ $128.03 |
15:59 | 100 @ $128.03 |
You are here: research